Antares Pharma, Inc. (ATRS) PT Set at $5.00 by HC Wainwright
Antares Pharma, Inc. (NASDAQ:ATRS) has been given a $5.00 price objective by stock analysts at HC Wainwright in a report released on Friday. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 34.05% from the stock’s current price.
A number of other analysts have also weighed in on ATRS. Chardan Capital started coverage on shares of Antares Pharma in a research note on Friday, June 23rd. They issued a “buy” rating and a $5.00 price objective on the stock. Vetr lowered shares of Antares Pharma from a “strong-buy” rating to a “buy” rating and set a $3.47 price target on the stock. in a research report on Monday, June 26th. Finally, Piper Jaffray Companies set a $4.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, July 26th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Antares Pharma presently has a consensus rating of “Buy” and a consensus price target of $4.34.
Shares of Antares Pharma (NASDAQ ATRS) traded down 38.07% during midday trading on Friday, hitting $2.31. 7,631,162 shares of the stock were exchanged. The stock’s market cap is $361.30 million. Antares Pharma has a 12 month low of $1.41 and a 12 month high of $4.09. The firm’s 50-day moving average is $3.23 and its 200-day moving average is $3.01.
Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.03) by $0.01. The firm had revenue of $13.42 million for the quarter, compared to analyst estimates of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. Equities research analysts predict that Antares Pharma will post ($0.11) earnings per share for the current year.
In other news, Director Thomas J. Garrity sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total value of $105,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. Company insiders own 11.60% of the company’s stock.
Several large investors have recently bought and sold shares of ATRS. Wells Fargo & Company MN raised its stake in Antares Pharma by 21.6% during the first quarter. Wells Fargo & Company MN now owns 767,600 shares of the specialty pharmaceutical company’s stock worth $2,180,000 after purchasing an additional 136,600 shares during the period. Bank of New York Mellon Corp increased its position in shares of Antares Pharma by 20.1% during the first quarter. Bank of New York Mellon Corp now owns 167,515 shares of the specialty pharmaceutical company’s stock valued at $476,000 after acquiring an additional 28,029 shares during the last quarter. M&T Bank Corp acquired a new stake in shares of Antares Pharma during the first quarter valued at about $227,000. California Public Employees Retirement System increased its position in shares of Antares Pharma by 14.4% during the first quarter. California Public Employees Retirement System now owns 934,300 shares of the specialty pharmaceutical company’s stock valued at $2,653,000 after acquiring an additional 117,300 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Antares Pharma by 4.3% during the first quarter. Vanguard Group Inc. now owns 5,619,088 shares of the specialty pharmaceutical company’s stock valued at $15,958,000 after acquiring an additional 232,349 shares during the last quarter. 36.77% of the stock is currently owned by hedge funds and other institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.